T he initial step in duplicating a cellular genome is the unwinding of a limited region of double-stranded DNA to form a small single-stranded DNA bubble (see the figure) (1) . In bacteria, archaea, and lower eukaryotes, the unwinding process begins at a sequence called the replication origin, which contains several conserved binding sites for a protein called the initiator. Binding of the initiator results in a nucleoprotein complex that "melts" DNA, forming the DNA bubble into which the replication machinery assembles. The architecture of the initiator-origin DNA nucleoprotein complex is largely unknown, but reports by Gaudier et al. on page 1213 (2) and by Dueber et al. on page 1210 (3) of this issue solve high-resolution structures of archaean initiator protein-origin DNA complexes that reveal several unexpected and novel features of initiator protein function.
Initiator proteins in all three domains of life share homology in a region that binds adenosine triphosphate (ATP), placing them in the AAA+ family of adenosine triphosphatases (4). AAA+ proteins are associated with diverse cellular activities and typically function as oligomers that remodel other macromolecules. Once bound to sites within a replication origin, initiator proteins oligomerize and use ATP to separate DNA strands in a nearby region (called the duplex unwinding element) that is enriched with adenine (A) and thymine (T) nucleotides. ATP binding and hydrolysis occurs at the interface between adjacent initiator proteins, which may underlie communication and cooperative action among subunits of an AAA+ protein oligomer.
DnaA, the replication initiator in the bacterium Escherichia coli, is monomeric in solution and oligomerizes upon binding to multiple initiator sites at a replication origin (5) . By contrast, the eukaryotic initiator ORC (origin recognition complex) is a tightly associated heterohexamer both in solution and when bound to DNA; five ORC subunits are thought to be AAA+ proteins (6) (7) (8) . Moreover, the replication origins of higher eukaryotes lack defined initiator binding sites (9) . But like those of bacteria, the replication origins of archaea contain several conserved initiator binding sites positioned near an A and T-rich unwinding element (10 (11, 12) . The winged helix motif consists of two DNA binding elements-a helixturn-helix and a β hairpin. The two DNA binding elements of the Orc winged helix enter both the major and minor grooves of DNA, widening them, in contrast to the typical case in which only one element of the winged helix enters a groove, and the other contacts the phosphodiester backbone.
Another unexpected finding from both studies is that the AAA+ domain of Orc binds DNA directly, rather than simply mediating protein oligomerization. Interaction
Structures of proteins for DNA replication in archaea suggest common mechanisms with sliding clamp loaders and DNA helicases. (15) and eukaryotic ORC (16, 17) ]. The present findings bring us closer to resolving how the replication of DNA gets started and how conserved or divergent the strategies are across species. P olymers have been used for decades as drug-delivery vehicles and implants owing to their useful mechanical properties (1-3), but were long thought too heterogeneous for use as bioactive pharmaceuticals in their own right. However, the physical properties of polymers can offer distinct advantages critical for treating human disease, including improved drug targeting and circulation, and polymer drugs have thus entered into routine clinical practice (4) .
Getting
Various strategies have advanced the biomedical application of polymeric drugs, including the chemical attachment of drugs to a polymer scaffold, the production of polymers directly from a polymerizable drug, and the use of polymers to sequester and eliminate toxic compounds. Polymer drugs of these categories are in or near clinical application. New approaches, mainly at the research stage, exploit improved understanding and control of polymer structure in the design of polymeric drugs with biological activities controlled by polymer architecture.
In some of the most developed and clinically applied approaches, the drug of interest is chemically attached to the polymer scaffold (see the first figure, top panel); these polymer-drug conjugates lead to improved drug targeting, circulation, and solubility. Attachment of targeting ligands to the polymer offers further enhancement in targeting, and judicious choice of the linker between the drug and polymer enables targeted liberation of drugs in response to pH, enzymatic, or redoxresponsive mechanisms (4, 5) . In a different approach, certain drugs (such as nonsteroidal anti-inflammatory drugs and antiseptics) can be polymerized directly to yield drugbased polymeric drugs that can be easily processed and that degrade to directly release the bioactive drug (6 
